Epidemiologist, “Coalition Builder” Mayne To Lead CFSAN
This article was originally published in The Tan Sheet
Executive Summary
Susan Mayne will succeed Michael Landa at the CFSAN helm in January 2015. Supplement industry stakeholders are encouraged FDA filled the post ahead of Landa’s retirement after feeling the impact of vacancies in CFSAN offices regulating the industry.
You may also be interested in...
In Brief: Abbott Outlook; CFSAN’s Landa To Retire; FTC Claim Substantiation
Abbott “on track” in China recovery; CFSAN seeks new director; FTC adds new substantiation elements to settlement; NAD advises iSatori to amend claims energy supplement claims; FDA wants proof deficiencies are corrected; and FDA warns about chelation supplement.
FDA Revision Of NDI Draft Guidance Starts With Grandfathered List
Trade groups say FDA committed to revisiting issues in the NDI draft guidance including how firms prove ingredients’ grandfathered status, notifications required for ingredients or finished products and data necessary to demonstrate NDI safety. The agency’s decision followed a meeting between industry allies Sens. Hatch and Harkin and FDA Commissioner Hamburg.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.